Novo-Med Zielinski I Wspolnicy Sp. j.

Katowice 20 trials 6 recruiting

20 Registered trials

6 Currently recruiting

Organisation

Novo-Med Zielinski I Wspolnicy Sp. j.

Location

Katowice, Poland

Identifier

ORG-100044516

Address

Ul. Jaworowa 34/1, 40-650, Poland

Departments

N/A
N/D
NA
Neurology
NIEPUBLICZNY ZAKŁAD OPIEKI ZDROWOTNEJ NOVO-MED
NZOZ Novo-Med
unknown

Clinical trials at this site (20)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures Pending

2025-520587-18-00 Focal Onset Seizures 4
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting

2022-502286-16-00 Primary Generalized Tonic-Clonic Seizures 5 2023-10-27
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy. Recruiting

2025-521640-38-00 Focal onset seizures or primary generalized tonic-cloni 5 2025-10-16
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508539-30-00 Refractory Focal Onset Epilepsy 4 2024-10-10
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients w… Recruiting

2023-507064-39-00 generalized Myasthenia Gravis 5 2024-09-26
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended

2024-514619-88-00 Relapsing Multiple Sclerosis 5 2022-03-18
An extension study to learn if Zilucoplan is safe and works over a long period in adult participants with generalized myasthenia gravis. Ended

2024-512399-37-00 Generalized Myasthenia Gravis 5 2020-12-29
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended

2024-514559-13-00 Focal Epilepsy 10 2024-11-26
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Relapsing Forms of Multiple Sclerosis 4 2023-10-03
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Focal Onset Seizures 5 2023-08-11
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S… Ended

2024-511610-20-00 Alzheimer's Disease 4 2022-11-08